TRASTUZUMABE DERUXTECANA/PROs T-DXd
OC Oncoclínicas RJ
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB DERUXTECAN IN THE ONCOCLINIS GROUP
Biomarker: HER+
Centro
OC Oncoclínicas RJ
Investigador principal
Diogo Rodrigues
Telefone
(21) 97138-0225 e (21) 2127-0281Critérios de inclusão
Female or male patients with HER+ metastatic malignancy of the breast who will start treatment with T-DXd; Age greater than 18 years.
Critérios de exclusão
Use of other concomitant antineoplastic therapies;
Patients for whom the physician responsible for prescribing T-DXd is from an institution other than the Oncoclínicas Group.
Coordenador(es)
Tamires Almeida
Entre em contato
Telefone(s)
Email(s)
Pesquisas clínicas
Confira mais informações sobre o programa de pesquisa clínica do Grupo Oncoclínicas.
Saiba mais
